Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
- ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL – - New Solid Tumors Technology Platform Revealed at SITC – - More Details on Solid Tumor Activities to be Discussed at Upcoming Investor Event – …